SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (593)4/14/1999 10:36:00 PM
From: Miljenko ZuanicRead Replies (1) | Respond to of 4974
 
You have my vote for SU6668.

I guess and hope ...*measurable plasma level*...means projected therapeutic level!

My understanding is that initial dose for SU6668 is bit higher than initial dose for SU5414 used in PI trials, so maybe some drug activity (surrogate markers) will be observed in few first pts cohorts, for iv and oral drug.

BTW, I wish that they reported on comparison data for iv versus oral drug bioaveability (plasma level and that sort of things). I guess it is something for direct contact with SUGN IR.

Miljenko



To: scaram(o)uche who wrote (593)4/15/1999 12:44:00 PM
From: RWReevesRead Replies (1) | Respond to of 4974
 
Pretty weak. I don't know why you like Phase I/II so much. The funnel is still pretty wide at this point.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News